Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Hepcludex
HEPCLUDEX 2 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 4–5
HOS-142395 · Präparat HOS-098824
4
As a precautionary measure, close clinical monitoring is warranted when NTCP substrates (e.g.
estrone-3-sulfate, fluvastatin, atorvastatin, pitavastatin, pravastatin, rosuvastatin, and thyroid
hormones) are co-administered with bulevirtide. When possible, co-administration of these substrates
should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T10:15:00Z · SHA-256 56ea5f48399773f9051c5a5cc519d740db7ee3cdff519ad40c96b180c39a4a0f · Passage 5bc00e5853559726857dc88ed0e9146e50b0f5615b01993b4d440cf65424c81d · Zeichen 346–661 im Abschnitt
Wechselwirkungen · Hepcludex
HEPCLUDEX 2 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-142397 · Präparat HOS-098824
In vitro an inhibition of OATP1B1/3 transporters by bulevirtide was observed, albeit only at a
concentration ≥ 0.5 µM, which is only reached in vivo after administration of high bulevirtide doses
(10 mg subcutaneous). The clinical relevance of these findings is unknown. As a precautionary
measure, close clinical monitoring is warranted when OATP1B1/3 substrates (e.g. atorvastatin,
bosentan, docetaxel, fexofenadine, glecaprevir, glyburide (glibenclamide), grazoprevir, nateglinide,
paclitaxel, paritaprevir, pitavastatin, pravastatin, repaglinide, rosuvastatin, simeprevir, simvastatin,
olmesartan, telmisartan, valsartan, voxilaprevir) are co-administered. When possible, co-
administration of these substrates should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fexofenadine (HOS-086255) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) olmesartan (HOS-112363) docetaxel (HOS-084505) glyburide (HOS-109273) voxilaprevir (HOS-108930) grazoprevir (HOS-108815) simeprevir (HOS-086302) telmisartan (HOS-085187) paclitaxel (HOS-087959) valsartan (HOS-088810) nateglinide (HOS-089675) bosentan (HOS-086291) paritaprevir (HOS-110301) repaglinide (HOS-086935) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T10:15:00Z · SHA-256 56ea5f48399773f9051c5a5cc519d740db7ee3cdff519ad40c96b180c39a4a0f · Passage e4ef1700e52190dc95fda7461e5b1ebeb8be97d2217f6773b4c102817dc6b0b5 · Zeichen 663–1396 im Abschnitt
Wechselwirkungen · Nilemdo
Nilemdo 180 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-143217 · Präparat HOS-098954
Transporter-mediated drug interactions
Bempedoic acid and its glucuronide weakly inhibit OATP1B1 and OATP1B3 at clinically relevant
concentrations. Coadministration of bempedoic acid with medicinal products that are substrates of
OATP1B1 or OATP1B3 (i.e., bosentan, fimasartan, asunaprevir, glecaprevir, grazoprevir,
voxilaprevir, and statins such as atorvastatin, pravastatin, fluvastatin, pitavastatin, rosuvastatin, and
simvastatin [see section 4.4]) may result in increased plasma concentrations of these medicinal
products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) asunaprevir (HOS-143218) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) fluvastatin (HOS-086305) voxilaprevir (HOS-108930) grazoprevir (HOS-108815) bosentan (HOS-086291) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-27T17:50:00Z · SHA-256 e22c45bda49313040ac4a284f068b61ba66ef21d794753c9c1627e320bff57f6 · Passage e3cde46d64bee9856eeb02defdf2dd1f019be752e72262dfa78d7864a952b079 · Zeichen 1595–2123 im Abschnitt
Wechselwirkungen · Kaftrio
Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets Kaftrio 75 mg/50 mg/100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-145644 · Präparat HOS-099389
ELX and M23-ELX inhibit uptake by OATP1B1 and OATP1B3 in vitro. TEZ/IVA increased the AUC of
pitavastatin, an OATP1B1 substrate, by 1.2-fold. Co-administration with IVA/TEZ/ELX in combination
with IVA may increase exposures of medicinal products that are substrates of these transporters, such as
statins, glyburide, nateglinide and repaglinide. When used concomitantly with substrates of OATP1B1 or
OATP1B3, caution and appropriate monitoring should be used. Bilirubin is an OATP1B1 and OATP1B3
substrate. In study 445-102, mild increases in mean total bilirubin were observed (up to 4.0 µmol/L
change from baseline). This finding is consistent with the in vitro inhibition of bilirubin transporters
OATP1B1 and OATP1B3 by ELX and M23-ELX.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glyburide (HOS-109273) nateglinide (HOS-089675) repaglinide (HOS-086935) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T16:15:00Z · SHA-256 04121cac1535ad5982d6257c33a1777a08c5914a9fce488aee1208cd9e01ad69 · Passage fd6c69156d4ef6bd02bb64d173f6b82b58c6b58fbb1ddd83b17501dca36c341a · Zeichen 4857–5597 im Abschnitt
Wechselwirkungen · Kaftrio
Kaftrio 60 mg/40 mg/80 mg granules in sachet Kaftrio 75 mg/50 mg/100 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 43
HOS-145695 · Präparat HOS-099389
ELX and M23-ELX inhibit uptake by OATP1B1 and OATP1B3 in vitro. TEZ/IVA increased the AUC of
pitavastatin, an OATP1B1 substrate, by 1.2-fold. Co-administration with IVA/TEZ/ELX in combination
with IVA may increase exposures of medicinal products that are substrates of these transporters, such as
statins, glyburide, nateglinide and repaglinide. When used concomitantly with substrates of OATP1B1 or
OATP1B3, caution and appropriate monitoring should be used. Bilirubin is an OATP1B1 and OATP1B3
substrate. In study 445-102, mild increases in mean total bilirubin were observed (up to 4.0 µmol/L
change from baseline). This finding is consistent with the in vitro inhibition of bilirubin transporters
OATP1B1 and OATP1B3 by ELX and M23-ELX.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glyburide (HOS-109273) nateglinide (HOS-089675) repaglinide (HOS-086935) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T16:15:00Z · SHA-256 04121cac1535ad5982d6257c33a1777a08c5914a9fce488aee1208cd9e01ad69 · Passage fd6c69156d4ef6bd02bb64d173f6b82b58c6b58fbb1ddd83b17501dca36c341a · Zeichen 4918–5658 im Abschnitt
Wechselwirkungen · Veklury
Veklury 100 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6–7
HOS-148230 · Präparat HOS-099858
6
Table 6: Effect of remdesivir on other drugs
Co-administered Remdesivir Interaction Recommendation
Drug Dose (mg) Geometric mean change (%) concerning
Dose (mg) co-administration
Midazolam 200 single dose Cmax ↑29% a
2.5 single dose AUCinf ↑20% a
No inhibition is expected when
co-administering remdesivir with substrate No dose adjustment
of CYP3A of remdesivir is
Midazolam 200 single dose Cmax ↑45%c required when it is
2.5 single dose followed by 100 once AUCinf ↑30%c co-administered with
daily (10 doses)b substrate of CYP3A
No induction is expected when
co-administering remdesivir with substrate
of CYP3A
Pitavastatin 200 single dose Cmax ↑5% a No dose adjustment
2 single dose AUCinf ↑17% a of remdesivir is
required when it is
No inhibition is expected when co-administered with
co-administering remdesivir with substrate substrate of
of OATP1B1/OATP1B3 OATP1B1/OATP1B3
NOTE: Interaction study conducted in healthy volunteers.
a. No effect = 1.00 (0.80-1.25).
b. Midazolam administered with last dose of remdesivir.
c. No effect = 1.00 (0.70-1.43)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): midazolam (HOS-086167) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-06T14:35:00Z · SHA-256 62bbcc5dde40e3d37fece6b0e45bdeb958676b6cca0903934c50ff2a8f5a02f8 · Passage c48960b04a6ce0de05d73537d0897b15a2497236371cd78fadc7567a2448ad1b · Zeichen 3577–5783 im Abschnitt
Wechselwirkungen · Sunlenca
Sunlenca 464 mg solution for injection · Abschnitt 4.5 · PDF-Seite 6–7
HOS-148304 · Präparat HOS-099874
6
Medicinal product by Effects on concentrations. Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with Sunlenca
Cmax
ERGOT DERIVATIVES
Dihydroergotamine Interaction not studied. Caution is warranted when
Ergotamine dihydroergotamine or ergotamine,
Plasma concentrations of these is co-administered with Sunlenca.
medicinal products may be
increased when co-administered
with lenacapavir.
PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS
Sildenafil Interaction not studied. Use of PDE-5 inhibitors for
Tadalafil pulmonary arterial hypertension:
Vardenafil Plasma concentration of PDE-5 Co-administration with tadalafil is
inhibitors may be increased when not recommended.
co-administered with lenacapavir.
Use of PDE-5 inhibitors for erectile
dysfunction:
Sildenafil: A starting dose of 25 mg
is recommended.
Vardenafil: No more than 5 mg in a
24-hour period.
Tadalafil:
• For use as needed: no more
than 10 mg every 72 hours
• For once daily use: dose not to
exceed 2.5 mg
CORTICOSTEROIDS (systemic)
Cortisone/hydrocortisone Interaction not studied. Co-administration of Sunlenca with
Dexamethasone corticosteroids whose exposures
Plasma concentrations of are significantly increased by
corticosteroids may be increased CYP3A inhibitors can increase the
when co-administered with risk for Cushing's syndrome and
lenacapavir. adrenal suppression. Initiate with
the lowest starting dose and titrate
Plasma concentrations of carefully while monitoring for
lenacapavir may decrease when co- safety.
administered with systemic
dexamethasone, which may result Caution is warranted when
in loss of therapeutic effect and systemic dexamethasone is
development of resistance. co-administered with Sunlenca,
particularly for long-term use.
Alternative corticosteroids should
be considered.
HMG-CoA REDUCTASE INHIBITORS
Lovastatin Interaction not studied. Initiate lovastatin and simvastatin
Simvastatin with the lowest starting dose and
Plasma concentrations of these titrate carefully while monitoring
medicinal products may be for safety (e.g. myopathy).
Atorvastatin increased when co-administered No dose adjustment of atorvastatin
with lenacapavir. is required.
Pitavastatind,i,l (2 mg single dose; Pitavastatin: No dose adjustment of pitavastatin
simultaneous or 3 days after AUC:↔ and rosuvastatin is required.
lenacapavir) Cmax:↔
Rosuvastatind,i,m (5 mg single dose) Rosuvastatin:
AUC:↑ 31%
Cmax:↑ 57%
ANTIARRHYTHMICS
Digoxin Interaction not studied. Caution is warranted and
therapeutic concentration
Plasma concentration of digoxin monitoring of digoxin is
may be increased when recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) tadalafil (HOS-086316) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) digoxin (HOS-086172) dexamethasone (HOS-084535) sildenafil (HOS-086162) hydrocortisone (HOS-148307) ergotamine (HOS-086154) dihydroergotamine (HOS-086152) pitavastatin (HOS-125743) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage 00e9d7399a80f2d2a9a0f459efd3beda50e916865cbf3466967e4abfe66e160f · Zeichen 6404–11764 im Abschnitt
Wechselwirkungen · Sunlenca
Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23–24
HOS-148341 · Präparat HOS-099874
23
Medicinal product by therapeutic Effects on concentrations. Recommendation concerning
areas Mean percent change in AUC, co-administration with Sunlenca
Cmax
CORTICOSTEROIDS (systemic)
Cortisone/hydrocortisone Interaction not studied. Co-administration of Sunlenca with
Dexamethasone corticosteroids whose exposures
Plasma concentrations of are significantly increased by
corticosteroids may be increased CYP3A inhibitors can increase the
when co-administered with risk for Cushing's syndrome and
lenacapavir. adrenal suppression. Initiate with
the lowest starting dose and titrate
Plasma concentrations of carefully while monitoring for
lenacapavir may decrease when co- safety.
administered with systemic
dexamethasone, which may result Caution is warranted when
in loss of therapeutic effect and systemic dexamethasone is
development of resistance. co-administered with Sunlenca,
particularly for long-term use.
Alternative corticosteroids should
be considered.
HMG-CoA REDUCTASE INHIBITORS
Lovastatin Interaction not studied. Initiate lovastatin and simvastatin
Simvastatin with the lowest starting dose and
Plasma concentrations of these titrate carefully while monitoring
medicinal products may be for safety (e.g. myopathy).
Atorvastatin increased when co-administered No dose adjustment of atorvastatin
with lenacapavir. is required.
Pitavastatin (2 mg single dose;
d,i,l
Pitavastatin: No dose adjustment of pitavastatin
simultaneous or 3 days after AUC:↔ and rosuvastatin is required.
lenacapavir) Cmax:↔
Rosuvastatind,i,m (5 mg single dose) Rosuvastatin:
AUC:↑ 31%
Cmax:↑ 57%
ANTIARRHYTHMICS
Digoxin Interaction not studied. Caution is warranted and
therapeutic concentration
Plasma concentration of digoxin monitoring of digoxin is
may be increased when recommended.
co-administered with lenacapavir.
SEDATIVES/HYPNOTICS
Midazolamd,i,n (2.5 mg single dose; Midazolam: Caution is warranted when
oral; simultaneous administration) AUC: ↑ 259% midazolam or triazolam, is
Cmax: ↑ 94% co-administered with Sunlenca.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) digoxin (HOS-086172) dexamethasone (HOS-084535) hydrocortisone (HOS-148307) triazolam (HOS-086168) midazolam (HOS-086167) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage 04f608f5ff93546fe1f7b83e8a9deb3141b0dd6a2fdcedbdf68a141374323bab · Zeichen 8599–12414 im Abschnitt
Wechselwirkungen · Joenja
Joenja 70 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-150275 · Präparat HOS-100280
OATP1B1, OATP1B3, and BCRP substrates
When co-administered, leniolisib increased rosuvastatin exposure 2-fold. Avoid concomitant use of
leniolisib with medicinal products that are OATP1B1, OATP1B3, and BCRP substrates (e.g.,
rosuvastatin, pitavastatin, letermovir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) rosuvastatin (HOS-086307) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-25T08:30:00Z · SHA-256 86ff542b4d3f7d0061b00035c52721373fd7e4b34a35a937a43304ec20dbf3fd · Passage 8612950de6feb1736873ec41339d5bd66a348e3f91417f32997d77544de4f3c6 · Zeichen 2067–2332 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.